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Five immunoglobulin G preparations, including one 5S F(ab')2 split product, were compared for activity
against common bacterial, viral, and protozoan pathogens. Standard assays were used to quantitate antibodies
to tetanus, diphtheria, cytomegalovirus, herpes simplex virus types 1 and 2, rubella virus, and Toxoplasma
gondii. Opsonization and killing of bacteria were examined by chemiluminescence methods using Streptococcus
pneumoniae types 5, 12F, and 14 and Staphylococcus aureus. Antibodies to the viral pathogens and T. gondii
were not detectable for the 5S immunoglobulin even at high concentrations (50 mg/ml) but were present in all
7S preparations at immunoglobulin concentrations of 10 mg/ml. Relatively lower activities for tetanus and
diphtheria antibody were also seen with the F(ab')2 product. Opsonizing capacity against all pneumococcal
serotypes and Staphylococcus aureus was lowest for the 5S product and highest for the commercially available
intravenous immunoglobulin product that is purified by using a pH 4.25 formulation. These data do not
support potential clinical usefulness of immunoglobulin G split products and suggest wide variations of specific
antibody among commercial intravenous immunoglobulin preparations.
There are 4 intravenous immunoglobulin (IVIG) prepara-
tions commercially available in the United States, while 15
to 20 additional products are being used in Europe and
Japan. These have largely replaced intramuscular immuno-
globulin for the maintenance therapy of patients with pri-
mary or secondary hypogammaglobulinemia. IVIG is also
approved for the management of acute and chronic idio-
pathic thrombocytopenic purpura. In addition, controlled
clinical trials have demonstrated efficacy for the treatment of
Kawasaki disease and for the prevention of the following
infections: sepsis in preterm neonates, sepsis in infants with
acquired immunodeficiency syndrome, and cytomegalovirus
(CMV) infection in transplant recipients. Open (uncon-
trolled) studies have suggested benefit in the treatment of
neonatal sepsis, chronic Epstein-Barr virus infection, and a
number of autoimmune diseases. These indications have
been reviewed recently (13).
There was no distinct therapeutic advantage for a native
IVIG product over a modified preparation in human efficacy
trials (12), although there are theoretic reasons to use
formulations which have utilized methodology to preserve
the molecular integrity of immunoglobulin G (IgG). There
are also theoretic advantages for F(ab'), split products,
including a reduced release of inflammatory mediators,
decrease in potential immune suppression, short serum
half-life, faster tissue penetration, and synergistic effects
with antibiotics (11).
Most important in evaluating potential efficacy for any
new IVIG material is first to determine the in vitro biologic
effects which are most likely to correlate with clinical
protection. Few investigations of this kind have been under-
taken (2, 11, 15). The present study was therefore designed
to compare the functional capacities of five IVIG prepara-
tions against important microbial pathogens. These products
were selected because various methods for purifying and
stabilizing them are utilized. One is an investigational 5S
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F(ab'), split immunoglobulin prepared by enzymatic diges-
tion.
MATERIALS AND METHODS
Total IgG levels were determined by the standard method
of rate nephelometry by using an automated immunochem-
ical system (Beckman Instruments, Inc., Fullerton, Calif.) as
described in detail previously (3). Specific antibodies to
herpes simplex virus types 1 and 2 (HSV-1 and -2), cytomeg-
alovirus, rubella virus, and Toxoplasma gondii were mea-
sured by an automatic analyzer (model PR50; Gilford Instru-
ment Laboratories, Inc., Oberlin, Ohio) using commercially
available enzyme-linked immunosorbent assay kits (Micro-
biological Associates Bioproducts, Walkersville, Md.) (16).
The anti-human IgG reagent in this assay is directed against
the whole IgG molecule. Tetanus and diphtheria antibodies
were measured by using a tannic acid hemagglutination
microtechnique (4). Titers are expressed as the reciprocal of
the highest dilution which demonstrated agglutination.
IVIG preparations. Five IgG products were examined in
these in vitro investigations: (i) 7S-IVIG, purified with a pH
4.25 formulation (Gamimune-N; Cutter Laboratory, Berke-
ley, Calif.); (ii) 7S-IVIG, treated at acid pH in the presence
of trace amounts of pepsin (Sandoglobulin; Sandoz AG,
Basel, Switzerland); (iii) sulfonated 7S-IVIG, fully reconsti-
tuted under physiologic conditions (Venimmun; Behring
Werke Gmb H, Marburg a.L., Federal Republic of Ger-
many); (iv) 5S-IVIG F(ab')l treated with pepsin (Gamma-
Venin; Behring Werke); and (v) an investigational 7S-IVIG,
nearly unmodified, treated with low concentrations of pepsin
(BI 61 011; Behring Werke). For the two commercially
available IVIG preparations, Gamimune-N and Sandoglob-
ulin, three different lots were combined for analysis.
Each IVIG product was diluted in Gey's balanced salt
solution (GBSS) to IgG concentrations ranging from 2.8 to 50
mg/ml. Most experiments were performed at 2.8 mg/ml since
this represents the final concentration of IVIG when given at
the usual recommended dose of 200 mg/kg of body weight.
CL. For chemiluminescence (CL) assays, venous blood
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ACTIVITIES OF IVIGs AND THE F(ab'). SPLIT PRODUCT
TABLE 1. Specific antibody in five IVIG preparations as measured by enzyme-linked immunosorbent assay
Prepn Specific antibody against pathogen'
(concn [mg/ml]) CMV HSV-1 HSV-2 Rubella T. gondil
Gamimune (2.8) 0.87 (MP) 0.49 (LP) 0.44 (LP) 0.68 (HP) 0.50 (MP)
Venimmun (2.8) 0.49 (MP) 0.35 (LP) 0.16 (N) 0.10 (N) 0.08 (N)
BI 61 011 (2.8) 0.60 (MP) 0.25 (LP) 0.25 (LP) 0.24 (MP) 0.11 (N)
Gamma-Venin (2.8) 0.07 (N) 0.07 (N) 0.07 (N) 0.02 (N) 0.00 (N)
Sandoglobulin (2.8) 0.22 (N) 0.35 (N) 0.21 (N) 0.12 (N) 0.11 (N)
Venimmun (10) 0.40 (LP) 0.51 (LP) 0.42 (MP) 0.27 (MP) 0.26 (LP)
Bt 61 011 (10) 0.71 (MP) 0.96 (MP) 0.69 (HP) 0.56 (HP) 0.28 (LP)
Gamma-Venin (10) 0.08 (N) 0.22 (N) 0.16 (N) 0.13 (N) 0.01 (N)
Sandoglobulin (10) 0.60 (MP) 0.83 (MP) 0.49 (MP) 0.41 (MP) 0.32 (LP)
Gamma-Venin (50) 0.20 (N) 0.28 (N) 0.25 (N) 0.10 (N) 0.10 (N)
Sandoglobulin (50) 0.60 (MP) 1.06 (MP) 0.62 (HP) 0.54 (HP) 0.54 (MP)
" Optical density readings. HP. High-range positive: MP. midrange positive: LP. low-range positive: N. negative.
was collected from a single adult volunteer, and polymor-
phonuclear leukocytes (PMN) were isolated by a dual Ficoll-
Hypaque gradient separation technique. The double-layer
gradient was prepared by placing 2 ml of monopoly resolving
medium (specific gravity, 1.114 g; Flow Laboratories, lnc.,
McLean, Va.) in a plastic centrifuge tube (16 by 100 m) and
carefully layering 2 ml of Histopaque (specific gravity, 1.077;
Sigma Chemical Co., St. Louis, Mo.) over the first. Four
milliliters of blood were gently layered on top of the gradi-
ents and centrifuged at 250 x g for 35 min in a swinging
bucket rotor at 20°C. The top fraction was discarded, and the
lower fraction (PMN) was collected and washed once with
Hanks balanced salt solution by centrifugation at 400 x g for
10 min. To remove contaminating erythrocytes, the cell
pellet was suspended in 0.84%, ammonium chloride and
incubated for 5 min in a 37°C water bath. The PMNs were
washed three additional times before adjusting the concen-
tration to 5 x 106/ml in GBSS.
Staphylococcus aureus bacteriophage type 502A and three
serotypes of Streptococ(iis pneunioniae were obtained from
the American Type Culture Collection, Rockville. Md.
These are Danish types 5 (6305), 12F (6312), and 14 (6414).
Organisms were inoculated into several tubes of Todd-
Hewitt broth and incubated at 37°C for 72 h. The suspen-
sions were centrifuged at 1,000 x g for 10 min at 25°C and
then washed and suspended in GBSS to a concentration of 5
x 108 to 5 x 109/ml. Bacteria were aliquoted and stored at
-70°C until used.
On the day of each assay, Staphvlococcus aureus and the
three S. pneuinonfiae serotypes in volumes of 0.2 ml each
were opsonized with 0.2 ml of IVIG-0.05 ml of guinea pig
complement for 30 min at 37°C. After incubation, 0.55 ml of
GBSS was added to each opsonized bacterial suspension.
This 1-ml volume was added to the reaction mixture vial for
a final bacteria/PMN ratio of 100:1.
IVIG opsonizing antibodies to bacteria were tested by
methods described in detail previously (1). CL was mea-
sured at room temperature in dark-adapted polypropylene
scintillation vials, with the photomultiplier tube of a Beck-
man LS 9000 liquid scintillation spectrophotometer set in the
out-of-coincidence mode. The vials contained a total of 5 x
106 PMN in 4 ml of GBSS and were equilibrated in the
scintillation counter until a stable background was reached.
CL was initiated by adding 1 ml of previously opsonized
bacteria (108 to 109) to each vial. All vials were counted for
30 s at approximately 7-min intervals for 90 min. CL was
expressed as peak activity during the reaction time. Maxi-
mum or peak counts per minute usually occurred between 35
and 60 min.
Initial assays were designed to examine nonspecific op-
sonization by determining results of CL activity by using
bacterium-absorbed serum. For these experiments, 108
killed organisms were added to 2.0 ml of serum, incubated at
30°C for 2 h. and centrifuged at 3,000 x g. Serum was
decanted and reincubated in a similar fashion twice more
with additional aliquots of bacteria. The resulting absorbed
serum was reconstituted with guinea pig complement prior
to the CL assays. Guinea pig complement alone was shown
not to generate any CL activity. In addition, serum from
patients with congenital agammaglobulinemia was incubated
by the same method to determine nonspecific opsonization.
This serum had measured immunoglobulin concentrations as
follows: IgG, 60 mg/dl; IgA, 0 mg/dl; and IgM, 32 mg/dl.
Data indicate that maximum counts per minute representing
nonspecific opsonization were 10 x 103 for type 5 S. pneu-
inonlae, 8 x 103 for type 12F, and 10 x 103 for type 14.
Pooled normal human sera yielded' peak CL responses at
least twice as high. thereby defining positive specific anti-
body activity. For presentation of the present data, nonspe-
cific opsonization was subtracted from total counts per
minute recorded in each assay.
RESULTS
At the expected in vitro concentration of IVIG (2.8 mg/ml)
following a 200-mg/kg iifuision, there was great variation in
specific antibody among the five preparations (Tables 1 and
2; Fig. 1 and 2). Most consistent was that the 5S immuno-
globu lin showed lower activity than those of all 7S prepara-
tions.
Antibodies to viral and protozoan pathogens. Gamimune
demonstrated the highest activity in enzyme-linked immuno-
sorbent assays for antibody to CMV, HSV-1, HSV-2, rubella
TABLE 2. Tetanus and diphtheria antibody in
five IVIG preparations
Activity' against:
Prepn"
Tetanus Diphtheria
Gamimune 1:2,187 1:729
Sandoglobulin > 1:10,000 > 1:10.000
Venimmun 1:243 1:27
Gamma-Venin 1:729 1:2.187
Bt 61 011 1:2,187 1:2.187
Each preparation was made up to a standard concentration of 2.8 mg/ml.
Expressed as the highest dilution with a positive hemagglutination re-
sponse.
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FIG. 1. Temporal traces of typical CL from 5 x 10 PMNs after
the addition of opsonized S. pneumoniae type 12F. Bacteria were
opsonized with Gamimune-N (S), Sandoglobulin (M), BI 61011 (0),
Venimmun (A), and Gamma-Venin (O).
virus, and T. gondii (Table 1). At concentrations of 2.8
mg/ml, antibody was detectable for all five pathogens. At
this IgG level, the investigational 7S-IVIG, BI 61 011, lacked
detectable antibody to T. gondii but was positive for all four
viral agents, while Venimmun had activity only in assays for
CMV and HSV-1 antibody. Both Sandoglobulin and Gam-
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FIG. 2. Temporal traces of typical CL from 5 x 106 PMNs after
the addition of opsonized Staphylococcus aureus phage type 502A.
Bacteria were opsonized with Gamimune-N (-), Sandoglobulin (A),
BI 61 011 (0), Venimmun (A), and Gamma-Venin (El).
ma-Venin were negative in all assays with IgG concentra-
tions of 2.8 mg/dl. At 10 mg/ml, Sandoglobulin was positive
in all five assays. Even at 50 mg/ml, Gamma-Venin remained
negative.
Antibodies to tetanus and diphtheria. Assays for antibodies
to these two bacterial pathogens were positive with all IVIG
preparations at a concentration of 2.8 mg/ml (Table 2).
Sandoglobulin yielded the highest titers at levels above the
maximum dilutions performed. The 5S product (Gamma-
Venin) yielded hemagglutination responses at lower dilu-
tions as contrasted with other products.
Bacterial opsonizing antibodies. Comparative results for
pneumococcal and staphylococcal opsonizing antibody as
measured by CL techniques were consistent in that all 7S
preparations yielded high opsonizing activity while the 5S
split product was always deficient. Data were similar for all
pneumococcal serotypes studied; those for type 12 are
presented in Fig. 1. Results for opsonizing experiments with
Staphylococcus aureus are summarized in Fig. 2. Measure-
ments above 8,000 cpm with this pneumococcal strain and
above 10,000 cpm for Staphylococcus aureus are higher than
what was defined as nonspecific opsonization, i.e., CL
responses with agammaglobulinemic or absorbed serum.
DISCUSSION
Intramuscular immune serum globulin has been used for
the prevention and treatment of infectious diseases since the
late 1930s (7). Diseases previously treated for which this
therapy is no longer recommended include polio, mumps,
rubella, and varicella-zoster virus infections. Currently, the
intramuscular preparation is used for replacement therapy of
patients with antibody deficiency states and for the preven-
tion of hepatitis A, hepatitis B, and measles. Hyperimmune
human serum globulin is also available for the prevention of
varicella-zoster virus infections, hepatitis B, and rabies.
IVIG was introduced for general clinical use in 1981 and
has since been the preferred maintenance therapy for im-
mune deficiency disorders. Intravenous therapy is of course
better tolerated by antibody-deficient patients since it avoids
the excessive pain accompanying intramuscular injections
with large volumes of material. The major limiting factor for
routine selection of IVIG is the high cost for these products.
Initially, it was assumed that modified IVIG, i.e., with
split IgG or altered Fc portions and absence of the IgG3
subclass, would prevent optimal functional capacity. The
first product commercially available, Gamimune, which was
reduced and alkylated, was indeed chemically modified in
this fashion. However, both in vitro and in vivo examination
indicated that such modification did not alter functional
capacity. In spite of these findings, this product was replaced
by one purified with a pH 4.25 formulation, Gamimune-N,
which retained the native IgG molecule. The three other
formulations commercially available in the United States are
likewise processed to maintain molecular integrity.
At the present time, there are 15 to 20 IVIG preparations
under investigation for clinical application. Among these are
split immunoglobulin products obtained by enzymatic diges-
tion yielding F(ab')2 or Fab antibodies. The theoretic advan-
tage of split over native immunoglobulin is that when
immune complexes are formed, their inability to interact
with Fc receptors reduces the potential for release of inflam-
matory mediators (10). Thus, systemic reactions from IVIG
infusions might be prevented. Another consequence of the
inability of split IgG to bind to Fc receptors is avoidance of
immunosuppression which may occur with complexes (8).
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ACTIVITIES OF IVIGs AND THE F(ab'), SPLIT PRODUCT
It has been reported that F(ab'), molecules are superior to
unsplit IgG in the elimination of haptens (9) and are equal in
their antibacterial and antiviral effects (6). These preliminary
observations prompted the present investigations, which
better defined in vitro activity of split immunoglobulin. Such
studies are essential before clinical application can be rec-
ommended.
These experiments were designed to compare and contrast
functional capacity of various IVIG formulations. Included
were two commercially available in the United States and
Europe (Gamimune-N and Sandoglobulin), one commer-
cially available in Europe but not the United States (Venim-
mun), an investigational 7S-IVIG reported to have excep-
tional antibacterial activity (BI 61 011), and one 5S-IVIG
F(ab')2 split product (Gamma-Venin) also commercially
available in Europe. There were three important findings in
these investigations. (i) The 5S immunoglobulin appeared
inferior to native material in its activity against a wide
spectrum of pathogens. (ii) There was great variation among
7S preparations for individual assays. (iii) No 7S product
was consistently superior to others.
Other studies have suggested that F(ab'), is equivalent to
native IVIG in functional activity (5, 13). One which exam-
ined in vitro opsonic and in vivo protective activity against
three enterobacterial strains found that protection by Fab
fragments varied among in vivo models (14); they concluded
that although there is a consistent loss in phagocytosis-
enhancing activity, this deficiency appears to be of relatively
greater importance in eliminating more virulent organisms.
Another study also suggested that native immune serum is
comparable to the F(ab'), fragment in augmenting the phago-
cytosis rate of bacteria (2). In these experiments the Fab/Fc,
Fab, and Fc fragments did not enhance neutrophil function.
Moreover, mice given fatal intraperitoneal inoculations of
bacteria could be protected with either whole IgG or F(ab'),.
These investigators concluded that the Fc region of the IgG
molecule is not predominantly responsible for opsonization.
Direct evidence has suggested that F(ab')2 fragments can
opsonize bacteria since this does not require the Fc portion
of the molecule (2). However, the present studies do not
support this contention, as CL responses were markedly
reduced following opsonization of pneumococci with 5S split
IVIG.
Although there were differences among the 7S-IVIG prod-
ucts in individual assays, it is unlikely that such differences
would indicate a therapeutic advantage. We and others have
been unable to show that exceptionally high in vitro antibody
responses for a particular IVIG preparation predict an
increase in clinical efficacy (12). It appears important to
demonstrate only that antibody to a particular pathogen is
present in consistently measurable concentrations.
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